Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38.

Abstract

Chemotherapy is usually the subsequent treatment for non-small cell lung cancer patients with acquired radioresistance after long-term fractionated radiotherapy. However, few studies have focused on the selection of chemotherapeutic drugs to treat lung adenocarcinoma patients with radioresistance. Our study compared the sensitivity changes of lung adenocarcinoma cells to conventional chemotherapeutic drugs under radioresistant circumstances by using three lung adenocarcinoma cell models, which were irradiated with fractionated X-rays at a total dose of 60 Gy. The results showed that the toxicities of paclitaxel, docetaxel and SN-38 were increased in radioresistant cells. The IC50 values of docetaxel and SN-38 decreased 0 ~ 3 times and 3 ~ 36 times in radioresistant cells, respectively. Notably, the A549 radioresistant cells were approximately 36 times more sensitive to SN-38 than the parental cells. Further results revealed that the downregulation of the efflux transporter BCRP by long-term fractionated irradiation was an important factor contributing to the increased cytotoxicity of SN-38. In addition, the reported miRNAs and transcriptional factors that regulate BCRP did not participate in the downregulation. In conclusion, these results presented important data on the sensitivity changes of lung adenocarcinoma cells to chemotherapeutic drugs after acquiring radioresistance and suggested that irinotecan (the prodrug of SN-38) might be a promising drug candidate for lung adenocarcinoma patients with acquired radioresistance.

• Authors: Yuqing Wang, Jie Huang, Qiong Wu, Jingjing Zhang, Zhiyuan Ma, Shenglin Ma, Shirong Zhang
• Journal: Investigational new drugs (Invest New Drugs) Vol. 39 Issue 2 Pg. 458-468 (04 2021) ISSN: 1573-0646 [Electronic] United States
• PMID: 33475937 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• ABCG2 protein, human
• ATP Binding Cassette Transporter, Subfamily G, Member 2
• Antineoplastic Agents
• Neoplasm Proteins
• Irinotecan

Topics

• A549 Cells
• ATP Binding Cassette Transporter, Subfamily G, Member 2 (drug effects)
• Antineoplastic Agents (pharmacology)
• Carcinoma, Non-Small-Cell Lung (pathology, therapy)
• Down-Regulation
• Humans
• Inhibitory Concentration 50
• Irinotecan (pharmacology)
• Lung Neoplasms (pathology, therapy)
• Neoplasm Proteins (drug effects)